NEW YORK (GenomeWeb News) – Sequenom has completed the acquisition of the Center for Molecular Medicine, a CLIA-certified clinical diagnostics lab based in Grand Rapids, Michigan.
Sequenom said in September that it would acquire the lab, which has been renamed the Sequenom Center for Molecular Medicine, for around $4 million.
The lab is a joint venture that was created last March between Spectrum Health, a non-profit health system, and the Van Andel Research Institute, an independent research institute. It includes Spectrum Health’s clinical resources and the Van Andel Research Institute’s genomics, proteomics, and bioinformatics know-how. CMM currently provides DNA and RNA extraction, DNA microarrays, multiplex detection, gene expression profiling, and other diagnostic services.
Sequenom said that it has formalized certain collaborative agreements with Spectrum Health and the Van Andel Research Institute.
“This acquisition is a major step in our SEQureDx strategy as it provides us with control over all aspects of commercialization,” Sequenom President and CEO Harry Stylli said in a statement. “In addition to a CLIA-certified facility, we gain the expertise from Spectrum Health in marketing and in developing critical sales and third-party reimbursement contracting strategies.”